Stock BCLI BRAINSTORM CELL THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Brainstorm Cell Therapeutics Inc.

Equities

BCLI

US10501E2019

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
0.5169 USD -3.80% Intraday chart for Brainstorm Cell Therapeutics Inc. -8.84% +89.34%
May. 20 BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit from Longer-Term Treatment with NurOwn CI
Apr. 17 Brainstorm Cell Therapeutics Inc. Announces Step Down of Stacy Lindborg as Co-CEO, Effective as of May 9, 2024 CI

Evolution of the average Target Price on Brainstorm Cell Therapeutics Inc.

Price target over the last 5 years

History of analyst recommendation changes

30af499836f2300e27a0afd0a185.20nB9IBJtpx1HmNWc0k1kV1abxMTpKPDMpROAOYbCmo.rQ6OgN8c-PVDXBcnA3pR6QsRMFRW9O32fKN8aKdhaV3jHIXByn7Z3zJEBA~7059661bd2a164fb0694cfe32fe93acd

Analyst Recommendations on Brainstorm Cell Therapeutics Inc.

Maxim Downgrades Brainstorm Cell Therapeutics to Hold From Buy MT
Fed rates at 7%: Is it on the cards? Our Logo
Maxim Group Adjusts Price Target on Brainstorm Cell Therapeutics to $10 From $5, Maintains Buy Rating MT
BRAINSTORM CELL THERAPEUTICS : Maxim Group Upgrades Brainstorm Cell Therapeutics to Buy From Hold MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.5169 USD
Average target price
2.5 USD
Spread / Average Target
+383.65%
High Price Target
2.5 USD
Spread / Highest target
+383.65%
Low Price Target
2.5 USD
Spread / Lowest Target
+383.65%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Brainstorm Cell Therapeutics Inc.

Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. BCLI Stock
  4. Consensus Brainstorm Cell Therapeutics Inc.